GlaxoSmithKline Pharmaceuticals Ltd. reported a 12% rise in net profit for the first quarter of FY2025, underpinned by resilient demand for key prescription brands and meticulous cost management. Revenue grew modestly amid stable therapeutic demand, particularly in respiratory and dermatology segments. The company's focus on operational efficiency, digital outreach, and expansion into smaller markets helped mitigate industry-wide pricing and regulatory pressures. Flagship brands like Augmentin and Calpol continued to anchor growth, while leaner cost structures bolstered margins.